Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 7, 2018. The report discloses changes in the interests of Persons Discharging Managerial Responsibilities (PDMRs) resulting from awards made under the GSK Deferred Investment Award programme on September 6, 2018.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on specific equity award transactions.
| Recipient | Position | Instrument | Volume | Price |
|---|---|---|---|---|
| Mr J Ford | SVP & General Counsel | American Depositary Shares (ADSs) | 6,320 | $39.78 |
| Mr R Simard | President, Pharmaceutical Supply Chain | Ordinary Shares | 11,060 | £15.254 |
Material Changes
The filing reports the initial notification of notional share awards for two PDMRs. These awards relate to employment prior to the individuals' appointment to GSK's Corporate Executive Team. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. Specific terms of the awards include:
- Vesting Date: February 14, 2021.
- Conditions: Vesting is subject to the individuals not having served notice or been terminated for cause.
- Payout: Awards do not accrue dividends and will be paid in cash upon vesting.
- Eligibility: Executive Directors are not eligible for this programme.
Investor Verification Points
- Confirm the vesting schedule and cash settlement terms for the Deferred Investment Award programme.
- Verify the specific roles and tenure of Mr J Ford and Mr R Simard relative to the award eligibility criteria.
- Note that this filing does not contain financial performance data; refer to the most recent Form 20-F or quarterly reports for financial metrics.